A new study has identified a human protein that can be targeted to block HIV infection, offering a potential breakthrough in the fight against AIDS. By inactivating this protein, called interleukin-2-inducible T cell kinase (ITK), researchers have found that HIV's ability to infect and replicate within immune cells is slowed or blocked.
A study found that micronutrient supplementation reduced TB recurrence rates in patients undergoing chemotherapy. The study showed a 45% overall reduction and a 63% decrease for HIV-infected patients.
Research published in PLOS Medicine found that interleukin-6 levels are associated with coronary heart disease, suggesting it could be a target for drug development. Two new methods were also developed to estimate HIV incidence based on changes in cross-sectional prevalence, showing sufficient accuracy for monitoring the epidemic.
Researchers have discovered how HIV evades the immune system by altering a key defence mechanism. The Nef protein interferes with the recognition of infected cells, making it difficult for the body to target and eliminate the virus.
Scientists believe that HIV's lack of protection against immune system activation makes it more virulent in humans. Researchers are studying whether artificially disabling this protective function could make SIVs more pathogenic in their natural hosts.
Researchers at Temple University found a correlation between CD163+/CD16+ monocyte subsets and viral load in HIV patients. This subset increase may serve as an early indicator of immune impairment and disease progression.
Researchers identified a genetic variant associated with severe tuberculosis (TB) in Vietnam, highlighting the importance of studying host-pathogen interactions. The study suggests that understanding genetic susceptibility to infectious diseases may lead to more targeted treatments and vaccines.
The article discusses the controversy surrounding when to initiate antiretroviral treatment in children with HIV. Dr. Steven Welch argues for deferred treatment to avoid poor adherence habits and drug resistance, while Professor Di Gibb advocates for early initiation to prevent disease progression and promote healthy growth.
UC Davis scientists discovered how salmonella becomes lethal for AIDS patients by finding the defect in immune response that allows it to cross the gut barrier and infect other organs. The study suggests Th17 cells play a crucial role in the inflammatory response, recruiting immune system cells to the site of infection.
A recent study found that infection with a mutated HIV strain is linked to improved survival in people who are newly infected. The researchers identified two specific mutations, A146X and T242N, which were associated with lower viral loads and higher CD4+ counts.
Researchers used mutations of NS5A phosphoprotein to disrupt virus particle production at an early stage of assembly, preventing infectious virus release. This finding offers a research tool and potential target for developing new anti-virals for treating hepatitis C.
The resurgence of syphilis in high-income countries has left many doctors unfamiliar with the disease's manifestations. The authors conclude that renewed training is necessary for health-care professionals, particularly in addressing increases among men who have sex with men and some high-risk heterosexual couples.
The rapid growth of the HIV/AIDS epidemic in London during the late 1990s was driven by transmission within clusters of sexual contacts, with individuals frequently passing the virus to others after becoming infected. Phylogenetic analysis revealed six large clusters and many smaller ones based on genetic relatedness of HIV viruses.
Researchers have discovered a way to manipulate the lengths of genetic pulses in HIV, favoring latency over replication. This finding offers promise for developing new treatments, as the 'switch' is a key factor in determining whether the virus becomes active.
Scientists at Albert Einstein College of Medicine genetically engineered immune cells to target and kill HIV-infected cells. This approach, using genes from elite controllers' immune systems, could lead to a new strategy for combating AIDS. The study shows promise in both test tubes and animal models.
A new TB screening test based on ELISPOT test has shown high sensitivity and specificity in detecting latent TB infection in HIV-infected individuals. The test was compared to the traditional tuberculin skin test (TST) and found to be more sensitive, but its effectiveness in severely immunosuppressed individuals remains unclear.
A study published in AIDS found that neural progenitor cells can form HIV reservoirs in the brain, similar to astrocytes. These cells have the potential to replicate the virus and transmit it outside the brain. Researchers hope to investigate how to protect these cells from the virus and develop new treatments.
A Canadian-US research team has solved a major genetic mystery: how a protein in some people's DNA guards against killer immune diseases like HIV. The discovery of FOX03a offers promise for HIV vaccine development and treatments for other immune diseases, such as cancer and rheumatoid arthritis.
A team of researchers identified a human gene called TRIM22 that can block HIV infection in cell culture by preventing virus assembly. The discovery shows the body has a natural defense mechanism against HIV, but research is needed to understand why it doesn't work in people infected with HIV.
Researchers create devices called glycodendrons to inhibit HIV transport and stimulate immune response against the virus. The approach targets a specific carbohydrate structure on the viral surface, mimicking an antibody that protects against HIV progression.
Research suggests that about one in four women with HIV expect pregnancy and motherhood, with younger women more likely to make this choice. The study highlights the need for clinicians to discuss pregnancy options with HIV-positive women of childbearing age.
A Phase II study found that the tenofovir gel was favorably self-applied and well-tolerated by HIV-negative women, with 80% following instructions to use the gel after sex. The researchers plan to proceed with larger studies to determine if the gel can prevent HIV infection.
The AIDS epidemic is stymied by a lack of political will and societal barriers such as gender inequality. Condom use is a cost-effective method for prevention but is resisted by fundamentalist groups. Despite the challenges, researchers are working to raise awareness and promote change.
University of Minnesota researchers have determined the atomic structure of APOBEC3G, a protein that inhibits HIV-1 infection. This discovery will help researchers manipulate the protein to combat HIV and develop methods to neutralize Vif, which triggers the destruction of APOBEC3G.
A recent study documents various stigmatizing behaviors by health-care personnel towards HIV-positive patients, including lack of eye contact, disdainful voice tone, and providing substandard care. The study highlights the need for all health-care personnel to be mindful of their actions to prevent misunderstandings and hard feelings.
A novel mathematical model predicts a rise in drug-resistant HIV infections among men in San Francisco, but surprisingly reduces the epidemic's severity. The Amplification Cascade Model suggests that resistance to certain classes of drugs will decline, while others will rise, leading to less infectious strains.
Researchers found that HIV persists in the gut despite long-term antiretroviral therapy, which failed to eradicate the virus from gut-associated lymphoid tissue. B-cell abnormalities also persisted, with memory B cells failing to recover after treatment.
Researchers have identified a new cellular receptor, integrin alpha 4 beta 7, that plays a crucial role in the early stages of HIV infection. The receptor, which guides immune cells to the gut, is targeted by the virus's gp120 protein, facilitating its entry into host cells.
A new study identifies autophagy as a crucial virulence-associated trait for Cryptococcus neoformans, a fungal pathogen that infects immunocompromised individuals. Autophagy helps the pathogen survive during nutrient scarcity and is essential for its virulence.
Scientists have discovered that immune cells confront viruses just inside the lymph node, not deep within the organ. This breakthrough could help design effective anti-virus vaccines against deadly viruses like HIV. The study sheds light on how the immune system operates during a viral infection.
A new study suggests that antiretroviral drugs used to treat HIV can also protect people from getting the AIDS virus, especially when two drugs are taken in combination before exposure to the virus. The best protection was seen in macaques that received a combination of two drugs, with all being protected from infection.
Researchers at Massachusetts General Hospital have discovered that grapefruit compound naringenin can block the secretion of hepatitis C virus from infected cells, a key step in maintaining chronic infection. This finding suggests that combining naringenin with antiviral medication may allow patients to clear the virus from their livers.
A study found that a low-dose regimen of nevirapine significantly reduced the risk of HIV transmission to breast-feeding infants, with a 40% decrease at 6 weeks and 33% decrease at 6 months. The extended-nevirapine regimen is considered safe and shows promise for preventing sexual transmission of HIV.
Researchers found a way to reverse HIV's deadly longevity by targeting its chemical changes that keep reservoirs alive. An existing ant-parasite drug, miltefosine, inhibits the PI3K/Akt pathway, which enables macrophages to survive despite surrounding toxicity.
A study in rural South Africa found that young people in school reported fewer sexual partners and engaged in protective behaviors, leading to lower HIV infection rates. The researchers suggest that increased access to education can play a critical role in HIV prevention.
A study finds that HIV prevalence falls more consistently among highly educated groups than less educated ones in sub-Saharan Africa. The research suggests that while HIV education campaigns led to a decline in infections among the well-educated, they had little impact on the least educated populations.
Researchers at UT Southwestern Medical Center have discovered that anti-retroviral drugs given daily before and after exposure to HIV can prevent vaginal transmission of the virus. This breakthrough could empower women worldwide to protect themselves from HIV infection.
Researchers have developed a new laboratory mouse model that can be used to test the efficacy of pre-exposure antiviral drugs to prevent HIV infection. The BLT mice have human blood cells, liver, and thymus tissue, making them susceptible to vaginal infection with HIV.
Researchers at UCLA have identified a key protein in dendritic cells that can stop HIV from 'budding', a crucial step in its life cycle. DC-SIGN and DC-SIGNR demonstrated strong inhibition of viral production, rendering released particles uninfectious.
The amfAR Mathilde Krim Fellowship program awards $1 million to bright young scientists working on prevention and treatment solutions for HIV/AIDS. Recipients include researchers studying HIV Tat-mediated transfer, TRIM5 modulation, biophysical studies of integrase-DNA complex, and morphogenesis of HIV-1 particles.
A research study in Kenya and the US found that an HIV isolate contains mutations making it vulnerable to the immune system. This could lead to effective AIDS vaccines to combat new infections estimated at 2.5 million annually worldwide. The study proposes a vaccine strategy based on envelope protein modifications.
A study found that nearly one out of 10 registered nurses reported at least one needlestick injury in the previous year, with many cases going unreported. The researchers emphasize the need for targeted risk reduction strategies tailored to non-hospital settings.
A new study found that treating worms in people with HIV does not significantly slow down the progression to AIDS. While some studies suggested a beneficial effect on viral load, there was no improvement in immune status or clinical condition.
A study published in Cell Press reveals that a component of human semen can enhance the ability of HIV to cause infection. The ingredient, called Semen-derived Enhancer of Virus Infection (SEVI), forms amyloid fibrils that capture and facilitate the entry of HIV into target cells.
Researchers found that newly HIV-infected men in the US dramatically shifted their behavior to choosing only unprotected sex with other infected individuals. This change reflects a systematic shift among men, mostly gay, to protect their partners from HIV infection.
A new investigational drug, tesamorelin, significantly improved symptoms of HIV lipodystrophy by reducing deep abdominal fat deposits and improving lipid abnormalities. Participants reported significant improvements in body image and reduced distress.
Research published in PLoS Medicine highlights the high risk of HIV infection among men who have sex with men in developing countries. Targeting HIV prevention programs to reach these men is crucial to curb transmission and reduce global burden.
The National Institutes of Health (NIH) recognizes the contributions of researchers and managers in the fight against HIV/AIDS. Since the first cases of AIDS were reported, NIH has established a comprehensive trans-NIH research effort to understand HIV biology, develop effective therapies, and prevent new infections.
Despite substantial progress against AIDS, the generalized HIV epidemic continues to rage on, driven by concurrent partnerships. Interventions such as abstinence and condom use have limited effectiveness in containing the spread of the disease, highlighting the need for a more nuanced approach to prevention.
A comprehensive review of evidence shows that pneumococcal conjugate vaccines can protect HIV-infected infants against pneumococcal disease. The vaccine can significantly improve the lives of HIV-infected children by reducing mortality rates.
Two studies led by Johns Hopkins Bloomberg School of Public Health researchers suggest that HIV subtype E is more virulent than other subtypes, leading to significantly shorter survival rates in Thailand. The studies found a median survival time from infection to death of 7.8 years for Thai men, compared to 11 years globally.
Cases of lymphogranuloma venereum have surged in the UK, primarily affecting men who have sex with men, with many also infected with HIV. Experts are urging caution on new diagnostic tests that require careful validation before widespread use.
Researchers found seven cases of HIV-1 superinfection in 36 high-risk women over five years after initial infection. The study suggests that immune responses from natural HIV-1 infection may not be effective against re-infection, raising questions about the reliability of current vaccines.
Researchers found that suppressing herpes simplex virus type 2 (HSV-2) significantly reduces levels of HIV in the blood and rectal secretions, making patients less likely to transmit the virus. This reduction in HIV levels could have a significant impact on transmission of HIV.
Research published in Sexually Transmitted Infections found that nearly one in five young Britons has sex with someone new while abroad, often choosing partners from the UK or Europe to reduce HIV transmission risk. This behavior is associated with risky sexual practices and highlights a gap in healthcare messaging for travelers.
Researchers have identified a potential new way of fighting against HIV infection by targeting human endogenous retroviruses (HERV). A vaccine containing HERV antigens could stimulate T-cells that target cells expressing HERV, potentially protecting people from becoming infected or limiting damage caused by HIV.
The new analyses revealed that the vaccine showed no measurable efficacy, and among individuals with background immunity to the adenovirus vector, there were more HIV infections in the vaccinees as compared to those in the placebo group. The STEP data will continue to be analyzed to better understand these results.
A single dose of tenofovir and emtricitabine can substantially reduce non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations in women given intrapartum nevirapine for perinatal HIV prevention. The study found a 53% lower risk of NNRTI mutations in the intervention group compared to controls.
A study published in Medical Care found that people infected with HIV continue to die and suffer from AIDS complications due to delayed diagnosis and treatment. Researchers discovered that patients who had received medical care for other illnesses were often not diagnosed with HIV infections earlier, leading to severe complications.
A University of North Carolina at Chapel Hill study finds that psychological factors, including traumatic life events like abuse, accelerate HIV disease progression and mortality. The research suggests that clinicians should screen patients for depression and trauma to improve health outcomes.